Shanghai Newsoara BioPharma in-licensed greater China rights to a Phase III oncolytic virus and other oncolytic viruses from Genelux in a $171 million deal. Newsoara will pay $10 million initially and up to $161 million in milestone payments, plus royalties. It will have manufacturing rights and be responsible for China development of Olvi-Vec. Genelux is currently planning a US Phase III trial of the candidate as a second-line therapy for ovarian cancer. Newsoara will also have exclusive China rights to other products from Genelux's oncolytic virus platform. More details.... Share this with colleagues: // //